COMMUNIQUÉS West-GlobeNewswire

-
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
02/04/2024 -
Nanobiotix annonce la finalisation de la partie escalade de la Phase 1 et la détermination de la dose recommandée pour la Phase 2 de NBTXR3 dans le traitement du cancer du poumon récurrent, inopérable et pouvant être réirradiés
02/04/2024 -
HeartSciences to Present at the LD Micro Invitational XIV Conference
02/04/2024 -
OneMedNet Completes Securities Purchase Agreement, Solidifying Cash Position to Accelerate Growth
02/04/2024 -
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
02/04/2024 -
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2024 -
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
02/04/2024 -
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
02/04/2024 -
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
02/04/2024 -
OneMedNet Announces CEO Succession Plan
02/04/2024 -
Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives
02/04/2024 -
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
02/04/2024 -
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
02/04/2024 -
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2024 -
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
02/04/2024 -
Crossject trading on Euronext to resume as usual on Wednesday April 3
02/04/2024 -
La cotation sur l’action de Crossject à Euronext reprendra comme d’habitude le mercredi 3 avril
02/04/2024 -
Wounded Warriors Family Support Honors 10 Veterans Welding Training Program Graduates
02/04/2024 -
Virbac acquired Sasaeah, a leading animal health player in Japan
02/04/2024
Pages